Moleculin Biotech Inc. (MBRX)
NASDAQ · Healthcare
Moleculin Biotech Inc. EBITDA 2016–2025
Moleculin Biotech Inc. annual/quarterly ebitda history and growth rate from 2016 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- Moleculin Biotech Inc. ebitda for the quarter ending March 31, 2026 was -7.9 M, a 33.05% increase year-over-year.
- Moleculin Biotech Inc. ebitda for the twelve months ending March 31, 2026 was -25.4 M, a 1.80% decrease year-over-year.
- Moleculin Biotech Inc. annual ebitda for 2025 was -25.0 M, a 5.66% decrease from 2024.
- Moleculin Biotech Inc. annual ebitda for 2024 was -26.5 M, a 10.13% decrease from 2023.
- Moleculin Biotech Inc. annual ebitda for 2023 was -29.5 M, a 3.30% decrease from 2022.
- Moleculin Biotech Inc. annual ebitda for 2022 was -30.5 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Moleculin Biotech Inc. EBITDA — FAQ
Moleculin Biotech Inc. (MBRX) ebitda over the last 10 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see MBRX's ebitda history?
The chart and table above show Moleculin Biotech Inc.'s ebitda by year and by quarter, including the growth rate.